Fig. 1: Inhibition of variant S–ACE2 binding.
From: Variant-proof high affinity ACE2 antagonist limits SARS-CoV-2 replication in upper and lower airways
SARS-CoV-2 S from WA1 (a), Delta (b), Beta (c) and BA.1 (d) were mixed with soluble ACE2 in combination with indicated concentrations of RBD-62, RBD from WA1 or an irrelevant malaria protein (PfCSP) to determine percentage binding inhibition relative to maximum binding without inclusion of inhibitor. Icons represent the average inhibition of duplicate technical replicates at each indicated dilution. IC50 and IC90 values (ng/mL) are indicated to the right of each graph and, along with the curves presented within the graphs, were calculated using the nonlinear regression analysis tool in Prism. The dotted lines indicate background inhibition observed for PfCSP. Source data are provided as a Source Data file.
